


Thailanstatin D

Cat. No.:	HY-139104
CAS No.:	1609105-89-6
Molecular Formula:	C ₂₈ H ₄₁ NO ₈
Molecular Weight:	519.63
Target:	DNA/RNA Synthesis; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Thailanstatin D, an analogue of Thailanstatin A, is able to inhibit AR-V7 gene splicing by interfering the interaction between U2AF65 and SAP155 and preventing them from binding to polypyrimidine tract located between the branch point and the 3' splice site. Thailanstatin D exhibits a potent tumor inhibitory effect on human CRPC xenografts leading to cell apoptosis ^[1] .								
In Vitro	<p>Thailanstatin D (0-50 nM; 4 hours) significantly decreases the protein levels of AR-V7 and other AR-Vs (AR splice variants)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>VCaP, 22RV1 and LN95 cells</td> </tr> <tr> <td>Concentration:</td> <td>0-50 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>4 hours</td> </tr> <tr> <td>Result:</td> <td>The mRNA levels of both AR-V7 and AR-FL were suppressed by Thailanstatin D in a dose-dependent manner.</td> </tr> </table>	Cell Line:	VCaP, 22RV1 and LN95 cells	Concentration:	0-50 nM	Incubation Time:	4 hours	Result:	The mRNA levels of both AR-V7 and AR-FL were suppressed by Thailanstatin D in a dose-dependent manner.
Cell Line:	VCaP, 22RV1 and LN95 cells								
Concentration:	0-50 nM								
Incubation Time:	4 hours								
Result:	The mRNA levels of both AR-V7 and AR-FL were suppressed by Thailanstatin D in a dose-dependent manner.								
In Vivo	<p>Thailanstatin D (300 µg/kg; ALZET osmotic pumps; daily for 4 days) significantly inhibits the tumor growth^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>NOD-SCID mice (Mice bearing 22RV1 xenografts)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>300 µg/kg</td> </tr> <tr> <td>Administration:</td> <td>ALZET osmotic pumps; daily for 4 days</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited the tumor growth.</td> </tr> </table>	Animal Model:	NOD-SCID mice (Mice bearing 22RV1 xenografts) ^[1]	Dosage:	300 µg/kg	Administration:	ALZET osmotic pumps; daily for 4 days	Result:	Significantly inhibited the tumor growth.
Animal Model:	NOD-SCID mice (Mice bearing 22RV1 xenografts) ^[1]								
Dosage:	300 µg/kg								
Administration:	ALZET osmotic pumps; daily for 4 days								
Result:	Significantly inhibited the tumor growth.								

REFERENCES

[1]. Wang B, et al. Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer. *Int J Cancer*. 2017;141(10):2121-2130.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA